Merus to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in several upcoming investor conferences. These include the Guggenheim Healthcare Talks/2022 Oncology Conference on February 10, the Citi 2022 Virtual Immuno-Oncology Summit on February 16, and the 11th Annual SVB Leerink Global Healthcare Conference on February 17. Webcasts of these events will be available on the Company's Investors page, with archived presentations accessible for a limited time.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics^®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

• Guggenheim Healthcare Talks/2022 Oncology Conference (fireside chat): Thursday, February 10 at 10:30-10:55 a.m. ET
• Citi's 2022 Virtual Immuno-Oncology Summit (fireside chat including Andrew Joe, M.D., Merus Chief Medical Officer): February 16 at 1:30-2:30 p.m. ET
• 11th Annual SVB Leerink Global Healthcare Conference (presentation): Thursday, February 17 at 12:00-12:30 p.m. ET
  

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter. 

FAQ

When will Bill Lundberg participate in the Guggenheim Healthcare Talks/2022 Oncology Conference?

Bill Lundberg will participate in the Guggenheim Healthcare Talks/2022 Oncology Conference on February 10, 2022, from 10:30 to 10:55 a.m. ET.

What is the schedule for Merus N.V.'s upcoming investor conferences?

Merus N.V. will participate in the following conferences: Guggenheim Healthcare Talks on February 10, Citi's Virtual Immuno-Oncology Summit on February 16, and SVB Leerink Global Healthcare Conference on February 17, 2022.

Where can I watch the webcasts of Merus N.V. presentations?

The webcasts of Merus N.V.'s presentations will be available on the Company's Investors page on their website.

What are the details for the 11th Annual SVB Leerink Global Healthcare Conference?

At the 11th Annual SVB Leerink Global Healthcare Conference, Merus N.V. will present on February 17, 2022, from 12:00 to 12:30 p.m. ET.

What is Merus's focus in the oncology sector?

Merus N.V. focuses on developing innovative, full-length multispecific antibodies, specifically Biclonics and Triclonics, for oncology treatments.